Marshall Wace
AXDX

Marshall Wace’s Accelerate Diagnostics AXDX Stock Holding History

Marshall Wace’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,653
Closed -$81K – 3408
2022
Q1 		$81K Sell
5,653
-3,209
-36% -$91.4K ﹤0.01% 3215
2021
Q4 		$464K Buy
8,862
+7,017
+380% +$391K ﹤0.01% 2845
2021
Q3 		$108K Buy
+1,845
New +$120K ﹤0.01% 2882
2021
Q2 		– Sell
-2,713
Closed -$225K – 2643
2021
Q1 		$225K Sell
2,713
-1,423
-34% -$144K ﹤0.01% 2222
2020
Q4 		$314K Buy
+4,136
New +$370K ﹤0.01% 1636
2020
Q3 		– Sell
-11,174
Closed -$1.69M – 1567
2020
Q2 		$1.69M Buy
11,174
+7,624
+215% +$752K 0.01% 846
2020
Q1 		$296K Buy
+3,550
New +$500K ﹤0.01% 1097
2019
Q2 		– Sell
-1,514
Closed -$318K – 1348
2019
Q1 		$318K Buy
+1,514
New +$284K ﹤0.01% 1249
2018
Q2 		– Sell
-930
Closed -$213K – 702
2018
Q1 		$213K Buy
+930
New +$244K 0.01% 513

Other funds holding AXDX

GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Marshall Wace's AXDX Position: Q2 2022 in Review

Marshall Wace sold out of Accelerate Diagnostics (AXDX) in Q2 2022, closing a stake of 5,653 shares — an estimated $81K sold.

Marshall Wace first reported a position in AXDX in Q1 2018 and held it in 9 quarters. The position peaked at $1.69M in Q2 2020. 74 funds tracked by Wall St. Rank hold AXDX as of Q2 2022.

  • Marshall Wace reported no remaining Accelerate Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Marshall Wace sold 5,653 Accelerate Diagnostics shares in Q2 2022, an estimated $81K.
  • Marshall Wace first reported a position in Accelerate Diagnostics in Q1 2018 and held it in 9 quarters.
  • Marshall Wace's Accelerate Diagnostics position peaked at $1.69M in Q2 2020.
  • 74 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2022.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.